Hereditary Oncology Testing
Test in Focus
In this "Test in Focus" episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology test offerings, which use next-generation sequencing to detect germline alterations associated with increased risk for various cancers. Our comprehensive panels, disease-specific panels, and single gene assays leverage the clinical expertise of Mayo Clinic physicians, enabling individualized insights on a patient’s risk of developing secondary cancers or a hereditary cancer syndrome.
“We know inherited genetic alterations contribute to about 10% to 20% of cancers overall,” Dr. Shen says. “However, more studies are showing that universal genetic testing actually detects more patients with hereditary cancer syndromes than a guideline-based approach.”
Test results can indicate the likelihood of a clinical diagnosis of a hereditary cancer syndrome, advance understanding of a patient’s risk of developing additional cancers, assist in management and treatment decisions, and rule out hereditary causes, Dr. Shen says. The biggest benefit of using Mayo Clinic testing, however, is access to expert-backed testing across the oncological spectrum.
“Cancers can result from both somatic and germline mutations,” Dr. Shen says. “This series of new genetic panels completes our comprehensive cancer testing menu and allows us to offer a one-stop shop genetic service to physicians and cancer patients.”
Listen to learn more.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
COMCP | Hereditary Common Cancer Panel
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.